Pierluigi Russo

List of Publications by Year in descending order

63 papers	**1,211** citations	394286 **19** h-index	414303 **32** g-index
63 all docs	**63** docs citations	**63** times ranked	**1632** citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of long‑term clinical response to interferon beta therapy in relapsing multiple sclerosis. Journal of Neurology, 2006, 253, 287-293.	1.8	113
2	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. European Heart Journal, 2015, 36, 2454-2462.	1.0	94
3	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Multiple Sclerosis Journal, 2007, 13, 412-419.	1.4	78
4	The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis. Journal of Neurology, 2004, 251, 432-439.	1.8	68
5	Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Annals of Oncology, 2010, 21, 2081-2087.	0.6	57
6	How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‑HTA parallel scientific advice. British Journal of Clinical Pharmacology, 2016, 82, 965-973.	1.1	57
7	Risk factors for uncontrolled hypertension in Italy. Journal of Human Hypertension, 2004, 18, 207-213.	1.0	56
8	Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis Journal, 2007, 13, 1086-1094.	1.4	50
9	MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. International Journal of Technology Assessment in Health Care, 2015, 31, 210-213.	0.2	44
10	Predictors of quality of life among patients with multiple sclerosis: An Italian cross-sectional study. Journal of the Neurological Sciences, 2007, 252, 121-129.	0.3	40
11	The impact of parallel regulatory‑health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. British Journal of Clinical Pharmacology, 2018, 84, 1013-1019.	1.1	34
12	Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. Journal of the American Medical Directors Association, 2016, 17, 168-172.	1.2	32
13	How many chronic myeloid leukemia patients who started a frontline second‑generation tyrosine kinase inhibitor have to switch to a second‑line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer Medicine, 2020, 9, 4160-4165.	1.3	32
14	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 578-585.	1.4	27
15	Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the???Introduction of New Disease-Modifying Agents. Clinical Drug Investigation, 2004, 24, 409-420.	1.1	23
16	Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 975-980.	1.4	23
17	Cocaine toxic effect on endothelium-dependent vasorelaxation: an in vitro study on rabbit aorta. Toxicology Letters, 2001, 123, 43-50.	0.4	22
18	Prescription Drug Use Among Older Adults in Italy: A Country-Wide Perspective. Journal of the American Medical Directors Association, 2014, 15, 531.e11-531.e15.	1.2	22

#	ARTICLE	IF	CITATIONS
19	Television viewing and personality structure in children. Personality and Individual Differences, 2002, 32, 977-990.	1.6	21
20	Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. Clinical Pharmacology and Therapeutics, 2016, 100, 730-742.	2.3	20
21	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidaseâ€4 inhibitor or a sulphonylurea: <scp>R</scp>esults from the <scp>OsMed H</scp>ealthâ€<scp>DB</scp> registry. Diabetes, Obesity and Metabolism, 2017, 19, 1416-1424.	2.2	18
22	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
23	Developing a paradigm of drug innovation: an evaluation algorithm. Drug Discovery Today, 2006, 11, 999-1006.	3.2	14
24	Sex Differences in Hemisphere Preference as Assessed by a Paper-And-Pencil Test. International Journal of Neuroscience, 2000, 100, 29-37.	0.8	12
25	Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer. Pharmacoeconomics, 2001, 19, 57-68.	1.7	12
26	Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. Journal of Evaluation in Clinical Practice, 2002, 8, 341-348.	0.9	12
27	Toxicological Effects of Beryllium on Platelets and Vascular Endothelium. Toxicology and Applied Pharmacology, 1997, 144, 262-267.	1.3	11
28	Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period. European Journal of Preventive Cardiology, 2022, 29, e149-e152.	0.8	11
29	Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA). Annals of Hematology, 2021, 100, 481-485.	0.8	11
30	A comparative economic analysis of simvastatin versus atorvastatin: Results of the surrogate marker cost-efficacy (SMaC) study. Clinical Therapeutics, 1999, 21, 1788-1796.	1.1	10
31	Sex Differences in EEG Correlates of a Self-reported Measure of Hemisphere Preference. International Journal of Neuroscience, 2001, 106, 109-121.	0.8	10
32	Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. Health Policy, 2021, 125, 1140-1145.	1.4	10
33	Drug Prices and Value of Oncology Drugs in Italy. Value in Health, 2021, 24, 1273-1278.	0.1	10
34	Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons. Journal of Clinical Psychiatry, 2016, 77, 1712-1718.	1.1	10
35	Cost-Effectiveness Study of Imipenem/Cilastatin versus Meropenem in Intra-Abdominal Infections. Digestive Surgery, 2000, 17, 164-172.	0.6	9
36	A Decision-Theoretic Framework for the Application of Cost-Effectiveness Analysis in Regulatory Processes. Pharmacoeconomics, 2009, 27, 645-655.	1.7	9

#	Article	IF	Citations
37	Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). Pharmacological Research, 2016, 111, 247-250.	3.1	9
38	Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease. Clinical Therapeutics, 2001, 23, 276-283.	1.1	8
39	Interferon alpha in the treatment of chronic hepatitis C in children: a metanalysis. Journal of Viral Hepatitis, 2003, 10, 210-214.	1.0	8
40	Proton pump inhibitors and hospital discharge rates for gastrointestinal events in italy: A national ecological study. Clinical Therapeutics, 2007, 29, 751-758.	1.1	8
41	Mortality in SARS-CoV-2 Hospitalized Patients Treated with Remdesivir: A Nationwide, Registry-Based Study in Italy. Viruses, 2022, 14, 1197.	1.5	8
42	Clinical and Economic Effects of Central Venous Catheters on Oncology Patient Care. Journal of Chemotherapy, 2007, 19, 309-314.	0.7	7
43	A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. Leukemia and Lymphoma, 2022, 63, 205-211.	0.6	7
44	Interaction Between Cognitive Style and School Environment: Consequences on Self-Evaluated Anxiety and Depression. International Journal of Neuroscience, 2001, 110, 79-90.	0.8	6
45	Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres. Journal of Immunoassay and Immunochemistry, 2008, 30, 40-50.	0.5	6
46	Neuroprotective effects of low-doses of aspirin. Human Psychopharmacology, 2001, 16, 193-194.	0.7	5
47	Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study. Journal of Evaluation in Clinical Practice, 2004, 10, 511-518.	0.9	5
48	Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 193-205.	0.7	5
49	The Italian compassionate use of sofosbuvir in <scp>HCV</scp> patients waitlisted for liver transplantation: A national realâ€life experience. Liver International, 2018, 38, 733-741.	1.9	5
50	Solitary Nodular Disease and Multinodular Goiter: a Retrospective Study on Suppressive Versus Replacement Levothyroxine Therapy. Endocrine Research, 1999, 25, 229-238.	0.6	4
51	EFFECTS OF SODIUM SELENITE ON VASCULAR SMOOTH MUSCLE REACTIVITY. Pharmacological Research, 2000, 41, 195-199.	3.1	4
52	Una prima valutazione economica dellâ€™impiego di rofecoxib versus FANS convenzionali nellâ€™artrosi. Pharmacoeconomics Italian Research Articles, 2001, 3, 81-89.	0.2	4
53	Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions. International Journal of Technology Assessment in Health Care, 2020, 36, 560-568.	0.2	4
54	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transplant International, 2017, 30, 1253-1265.	0.8	3

#	Article	IF	Citations
55	CYCLIC ESTROGENâ€"PROGESTIN HORMONE THERAPY AS A NEW THERAPEUTIC APPROACH IN THE TREATMENT OF FUNCTIONAL ALTERATIONS OF THE HYPOTHALAMUS-PITUITARY-OVARY AXIS: CASE REPORTS. Endocrine Research, 2002, 28, 155-160.	0.6	2
56	Cost-effectiveness of direct acting oral anticoagulants in the prevention of thromboembolic complications. Journal of Cardiovascular Medicine, 2019, 20, 500-503.	0.6	2
57	Analisi costo-efficacia di due combinazioni sequenziali di trattamenti di eradicazione dellâ€™Helicobacter pylori. Pharmacoeconomics Italian Research Articles, 2001, 3, 15-25.	0.2	1
58	Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 227-236.	0.7	1
59	Generic and biosilimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA). Journal of Generic Medicines, 2015, 12, 79-80.	0.0	1
60	How reliable are ICERâ€™s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality. Global & Regional Health Technology Assessment, 0, 9, 31-35.	0.2	1
61	Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice. Current Therapeutic Research, 2004, 65, 398-412.	0.5	0
62	Un modello di analisi del valore dellâ€™informazione per la valutazione di costo-efficacia nellâ€™ambito del processo regolatorio. Pharmacoeconomics Italian Research Articles, 2010, 12, 5-16.	0.2	0
63	Mortality after Remdesivir Treatment of Pneumonia in Hospitalised Patients with Laboratory Confirmed COVID-19: National Data in the Italian Real-World Practice Collected by the AIFA Monitoring Register.. SSRN Electronic Journal, 0, , .	0.4	0